Influence of Low Molecular Weight Heparin and Low Molecular Weight Dextran Sulfate on the Inhibition of Coagulation Factor XIa by Serpins

Summary

We investigated the influence of low molecular weight dextran sulfate (LMWdxs) and low molecular weight heparins (LMWH: dalteparin, enoxaparin and nadroparin) on the inhibition of FXIa by C1-inhibitor, α₁-antitrypsin, α₂-antiplasmin and antithrombin in a purified system and in plasma.

The second order rate constant for inactivation of FXIa by C1-inhibitor, α₁-antitrypsin, α₂-antiplasmin, and antithrombin was 1.23, 0.056, 0.33 and 0.59 × 10³ M^–1 s^–1, respectively.

LMWdxs and LMWH dose-dependently increased the second order rate constant of the inactivation of FXIa by C1-inhibitor up to 39-fold. The second order rate constant of the inactivation of FXIa by anti-thrombin was increased up to 6-fold by LMWH, whereas LMWdxs had no effect. In plasma, FXIa was inactivated to about 50% by C1-inhibitor, while the other serpins contributed together to the remaining 50% of plasma’s inhibitory capacity towards FXIa. In the presence of LMWdxs or LMWH, FXIa was inactivated in plasma to more than 90% by C1-inhibitor. LMWH at maximal therapeutic plasma levels enhanced the contribution of antithrombin to the inactivation of FXIa in plasma up to 5-fold.

In conclusion, we found that the tested low molecular weight glycosaminoglycans dalteparin, enoxaparin and nadroparin and LMWdxs stimulate inactivation of FXIa by C1-inhibitor in a system using purified proteins as well as in plasma. Furthermore, LMWH but not LMWdxs slightly enhanced FXIa inhibition by antithrombin.

• References

• 1 Kitchens CS. Factor XI: a review of its biochemistry and deficiency. Semin Thromb Hemost 1991; 17: 55-72.
• 2 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
• 3 Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. J Clin Invest 1977; 59: 1167-75.
• 4 Bouma BN, Griffin JH. Human blood coagulation factor XI. Purification, properties and mechanism of activation by activated factor XII. J Biol Chem 1977; 252: 6432-7.
• 5 Kurachi K, Davie EW. Activation of human factor XI (plasma thromboplastin antecedent) by factor XIIa (activated Hageman factor). Biochemistry 1977; 16: 5831-9.
• 6 van der Graaf F, Greengard JS, Bouma BN, Kerbiriou DM, Griffin JH. Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem 1983; 258: 9669-75.
• 7 Forbes CD, Pensky J, Ratnoff OD. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified C1-inactivator. J Lab Clin Med 1970; 76: 809-15.
• 8 Heck LW, Kaplan AP. Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by α₁-antitrypsin. J Exp Med 1974; 140: 1615-29.
• 9 Soons H, Janssen-Claessen T, Tans G, Hemker HC. Inhibition of factor XIa by antithrombin III. Biochemistry 1987; 26: 4624-9.
• 10 Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-7.
• 11 Saito H, Goldsmith GH, Moroi M, Aoki N. Inhibitory spectrum of α₂-plasmin inhibitor. Proc Natl Acad Sci USA 1979; 76: 2013-7.
• 12 Wuillemin WA, Minnema M, Meijers JCM. et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-26.
• 13 Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991; 60: 443-75.
• 14 Hirsh J, Levin MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
• 15 Beeler DL, Marcum JA, Schiffman S, Rosenberg RD. Interaction of factor XIa and antithrombin in the presence and absence of heparin. Blood 1986; 67: 1488-92.
• 16 Scott CF, Colman RW. Factors influencing the acceleration of human factor XIa inactivation by antithrombin III. Blood 1989; 73: 1873-9.
• 17 Soons H, Tans G, Hemker HC. The heparin-catalysed inhibition of human factor XIa by antithrombin III is dependent on the heparin type. Biochem J 1988; 256: 815-20.
• 18 Nuijens JH, Huijbregts CCM, Cohen M. et al. Detection of activation of the contact system of coagulation in vitro and in vivo: Quantitation of activated Hageman factor-C1-inhibitor and kallikrein-C1-inhibitor complexes by specific radioimmunoassays. Thromb Haemost 1987; 58: 778-84.
• 19 Dors DM, Nuijens JH, Huijbregts CC, Hack CE. A novel sensitive assay for functional factor XII based on the generation of kallikrein-C1-inhibitor complexes in factor XII-deficient plasma by glass-bound factor XII. Thromb Haemost 1992; 67: 644-8.
• 20 Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem 1996; 271: 12913-8.
• 21 Tankersley DL, Alving BM, Finlayson JS. Activation of factor XII by dextran sulfate: the basis for an assay of factor XII. Blood 1983; 62: 448-56.
• 22 Scott CF, Schapira M, James HL, Cohen AB, Colman RW. Inactivation of factor XIa by plasma protease inhibitors. Predominant role of α₁-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 1982; 69: 844-52.
• 23 Frydman A. Low-molecular weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26 (Suppl. 02) 24-38.
• 24 Meijers JC, Vlooswijk RA, Bouma BN. Inhibition of human blood coagulation factor XIa by C1 inhibitor. Biochemistry 1988; 27: 959-63.
• 25 Oshima G. The molecular-mass dependence of dextran sulfate enhancement of inactivation of thrombin and fibrinogen and on factor Xa neutralization by antithrombin III. Biol Chem Hoppe Seyler 1989; 370: 715-21.
• 26 Pixley RA, Danishefsky I. Action of heparin on the inhibition of thrombin by α₁-proteinase inhibition. Biochemistry 1983; 22: 4810-3.
• 27 Frommherz KJ, Faller B, Bieth JG. Heparin strongly decreases the rate of inhibition of neutrophil elastase by α₁-proteinase inhibitor. J Biol Chem 1991; 266: 15356-62.
• 28 Wuillemin WA, Hack CE, Bleeker WK, Biemond BJ, Levi M, ten Cate H. Inactivation of factor XIa in vivo: studies in chimpanzees and in humans. Thromb Haemost 1996; 76: 549-55.
• 29 Wuillemin WA, Bleeker WK, Agterberg J, Rigter G, ten Cate H, Hack E. Clearance of human factor XIa-inhibitor complexes in rats. Br J Hematol 1996; 93: 950-4.
• 30 Wuillemin WA, Fijnvandraat K, Derkx BHF. et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995; 74: 1436-41.
• 31 Schapira M. Major inhibitors of the contact phase coagulation factors. Semin Thromb Hemost 1987; 13: 69-78.
• 32 Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-9.
• 33 de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest 1984; 73: 1542-9.
• 34 Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462-8.
• 35 van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-58.
• 36 Schapira M, Scott CF, Colman RW. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 1981; 20: 2738-43.
• 37 Wuillemin WA, te Velthuis H, Lubbers YTP, de Ruig CP, Eldering E, Hack CE. Potentiation of C1-inhibitor by glycosaminoglycans. J Immunol 1997; 159: 1953-60.
• 38 Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.